ArticleMolecular diagnosis & therapy2012
The clinico-pathologic role of microRNAs miR-9 and miR-151-5p in breast cancer metastasis.
Article in Molecular diagnosis & therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 49 citations in OpenAlex.
- Upregulation of miR-151a-5p in high DFI sperm induces DNA damage and mitochondrial dysfunction by targeting INPP4B and VAMP1.Reproductive biology and endocrinology : RB&E · 2025Article
- Extracellular vesicle-mediated chemoresistance in breast cancer: focus on miRNA cargo.Extracellular vesicles and circulating nucleic acids · 2025Review
- Unraveling non-coding RNAs in breast cancer: mechanistic insights and therapeutic potential.Medical oncology (Northwood, London, England) · 2024Review
- Review
- Oral SpirocheteInternational journal of molecular sciences · 2023Article
- Specific microRNA Signature Kinetics inInternational journal of molecular sciences · 2023Article
- Screening of miRNAs associated with lymph node metastasis in Her-2-positive breast cancer and their relationship with prognosis.Journal of Zhejiang University. Science. B · 2020Article
- In silico prediction of potential miRNA-disease association using an integrative bioinformatics approach based on kernel fusion.Journal of cellular and molecular medicine · 2020Article
- miR-9-5p as a Regulator of the Androgen Receptor Pathway in Breast Cancer Cell Lines.Frontiers in cell and developmental biology · 2020Article
- Unravelling site-specific breast cancer metastasis: a microRNA expression profiling study.Oncotarget · 2017Article
- MiR-9 Promotes ApoptosisCurrent chemical genomics and translational medicine · 2017Article
- miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype.Oncotarget · 2016Article
- Article
- MicroRNA Expression Profiles in Papillary Thyroid Carcinoma, Benign Thyroid Nodules and Healthy Controls.Journal of Cancer · 2016Article
- Mitochondria-related miR-151a-5p reduces cellular ATP production by targeting CYTB in asthenozoospermia.Scientific reports · 2015Article
- Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer.Oncotarget · 2015Article
- Autocrine/Paracrine Human Growth Hormone-stimulated MicroRNA 96-182-183 Cluster Promotes Epithelial-Mesenchymal Transition and Invasion in Breast Cancer.The Journal of biological chemistry · 2015Article
- Arsenic responsive microRNAs in vivo and their potential involvement in arsenic-induced oxidative stress.Toxicology and applied pharmacology · 2015Article
- Increased expression of microRNA-9 predicts an unfavorable prognosis in human glioma.Molecular and cellular biochemistry · 2013Article
- Functional microRNAs in Alzheimer's disease and cancer: differential regulation of common mechanisms and pathways.Frontiers in genetics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundMicroRNAs (miRNAs) may function as suppressors or promoters of tumor metastasis according to their messenger RNA targets. Previous studies have suggested that miR-9 and miR-151-5p are associated with metastasis in breast cancer and hepatocellular carcinoma, respectively. We aimed to further establish the potential roles of miR-9 and miR-151-5p in tumor invasion and metastasis and investigate their use as biomarkers.
methodsWe used quantitative real-time PCR (qRT-PCR) to measure differences in miR-9 and miR-151-5p expression between primary breast tumors and their lymph-node metastases in 194 paired tumor samples from 97 patients. We also correlated expression levels with histologic data to investigate their utility as biomarkers.
resultsThere were no significant differences in miR-9 expression between the primary tumors and lymph nodes; however, miR-151-5p expression was significantly lower in the lymph-node metastases than in their corresponding tumors (p < 0.05). miR-9 levels were elevated in primary breast tumors from patients diagnosed with higher-grade tumors (p < 0.05); however, no differences were observed in miR-151-5p levels between different grades of tumor. Interestingly, miR-9 levels were elevated in invasive lobular carcinomas (ILC) compared with invasive ductal carcinomas (IDC; p < 0.01).
conclusionsIn aggregate, these data suggest that miR-151-5p upregulation may suppress metastasis in primary breast tumors. Both miRNAs may serve as useful biomarkers in future clinical trials in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.